Open an account

Nuvectis Pharma

NVCT · NASDAQ

$20.59+$1.65 (+8.71%)TodayMarket closed ·
Prev close $18.94

About NVCT

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is headquartered in Fort Lee, New Jersey and currently employs 13 full-time employees. The company went IPO on 2022-02-04. The firm is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.

Employees
13
Headquarters
Fort Lee, New Jersey
Listed
Feb 4, 2022
Sector
Health Care
Industry
Biotechnology
Website
nuvectis.com

NVCT key statistics

Market cap
672.14M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
179.05K
Volume
148.78K
Open price
$19.09
High today
$20.91
Low today
$17.85
52 Week high
$29.28
52 Week low
$5.55

Nuvectis Pharma (NVCT) at a glance

Nuvectis Pharma (NVCT) last traded at $20.59, with a market cap of 672.14M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $17.85 and $20.91. The current price is 15.4% above the day's low and 1.5% below its high.

Volume so far is 148.78K shares, in line with the average of 179.05K shares a day.

Over the past year Nuvectis Pharma has ranged from $5.55 to $29.28, and now sits 63% of the way up that range.

Nuvectis Pharma met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.30 per share against an estimate of -$0.2672.

The average analyst price target is $36.11, 75.4% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $36.11
Low
$30.30
Now
$20.59
High
$42.00

NVCT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 12.3% on average.

  1. Q3 FY24: reported -$0.24 per share against an estimate of -$0.2574
  2. Q4 FY24: reported -$0.36 per share against an estimate of -$0.2581
  3. Q1 FY25: reported -$0.27 per share against an estimate of -$0.2591
  4. Q2 FY25: reported -$0.30 per share against an estimate of -$0.2601
  5. Q3 FY25: reported -$0.33 per share against an estimate of -$0.2525
  6. Q4 FY25: reported -$0.31 per share against an estimate of -$0.3035
  7. Q1 FY26: reported -$0.26 per share against an estimate of -$0.3162
  8. Q2 FY26: reported -$0.30 per share against an estimate of -$0.2672

NVCT news

  • Tanya Rawat

    Nuvectis Pharma Jumps 20% To 52-Week High — Here's Why NVCT Stock Is Trending

  • Press releaseBusiness Wire

    Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation

  • Press releaseBusiness Wire

    Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Avi Kapoor

    S&P 500 Moves Lower; US Crude Oil Inventories Increase

  • Avi Kapoor

    Dow Falls Over 100 Points; US Producer Prices Rise In October

  • Avi Kapoor

    US Stocks Edge Lower; Cisco Earnings Top Views

  • Press releaseBusiness Wire

    PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.